Suchergebnisse - "Lederer, David J"

PubPharm (27)

1

Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma : VOYAGE Study

enthalten in: The journal of allergy and clinical immunology. In practice | 2024

von Bacharier, L. | Guilbert, T. | Katelaris, C. | +13

2

Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma

enthalten in: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology | 2023

von Jackson, D. | Bacharier, L. | Phipatanakul, W. | +19

3

Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019 : A Randomized Clinical Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022

von Sivapalasingam, S. | Lederer, D. | Bhore, R. | +37

4

Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma : An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial

enthalten in: Chest | 2022

von Sher, L. | Wechsler, M. | Rabe, K. | +14

CommentIn: Chest. 2022 Jul;162(1):4-5. - PMID 35809937

5

Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma

enthalten in: The New England journal of medicine | 2021

von Bacharier, L. | Maspero, J. | Katelaris, C. | +123

CommentIn: N Engl J Med. 2021 Dec 9;385(24):2297-2298. - PMID 34879454

6

Baseline Severe Acute Respiratory Syndrome Viral Load Is Associated With Coronavirus Disease 2019 Severity and Clinical Outcomes : Post Hoc Analyses of a Phase 2/3 Trial

enthalten in: The Journal of infectious diseases | 2021

von Boyapati, A. | Wipperman, M. | Ehmann, P. | +10

7

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : a double-blind, randomised, placebo-controlled, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2020

von Maher, T. | Corte, T. | Fischer, A. | +8

CommentIn: Lancet Respir Med. 2020 Feb;8(2):126-127. - PMID 31578170

8

Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE) : a phase 2, randomised, double-blind, placebo-controlled trial

enthalten in: The Lancet. Respiratory medicine | 2020

von Richeldi, L. | Fernández Pérez, E. | Costabel, U. | +14

CommentIn: Lancet Respir Med. 2020 Jan;8(1):2-3. - PMID 31575507

9

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis : Optimising Trial Design

enthalten in: Advances in therapy | 2019

von Santermans, E. | Ford, P. | Kreuter, M. | +11

10

Low Dose Carbon Monoxide Exposure in Idiopathic Pulmonary Fibrosis Produces a CO Signature Comprised of Oxidative Phosphorylation Genes

enthalten in: Scientific reports | 2019

von Casanova, N. | Zhou, T. | Gonzalez-Garay, M. | +15